EBITDA CAGR uses clean operating EBITDA derived from reported operating income plus depreciation and amortization.
Over longer horizons, EBITDA CAGR averages -10.38% over 3 years and 1.57% over 5 years; the trailing 12 months came in at -7.87%. EBITDA CAGR shows how the company's operating profitability has grown before depreciation and amortization. This reflects the growth of the core business's cash-operating earnings power, independent of capital-intensity and accounting depreciation choices.
REGN EBITDA CAGR Chart
Regeneron Pharmaceuticals, Inc. (REGN)
tgmcharts.com
REGN Quarterly EBITDA Growth (YoY)
EBITDA growth vs the same quarter one year earlier, last 40 quarters.
tgmcharts.com
EBITDA
REGN Quarterly EBITDA
$1.54B
Reported quarterly EBITDA; no daily interpolation.
